# Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

> **NCT06735820** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **AeRang Kim** · enrollment: 45 (estimated)

## Conditions studied

- Malignant Peripheral Nerve Sheath Tumor (MPNST)
- Neurofibromatosis 1 (NF1)
- Atypical Neurofibroma

## Interventions

- **DRUG:** APG-115
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT06735820
- **Lead sponsor:** AeRang Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06735820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06735820, "Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06735820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*